Pharmaceutical Companies Seek Stability in Trump Drug Cost Fight
- Pfizer spends more on lobbyists, while Merck pays out less
- Administration continues campaign to bring down prices
Photographer: Chris Ratcliffe/Bloomberg
This article is for subscribers only.
Several major pharmaceutical companies lowered their spending on lobbyists in the second quarter of 2018, a time of uncertainty as President Donald Trump’s administration continued its campaign to lower drug costs for consumers.
Pharmaceutical Research and Manufacturers of America spent $5.54 million between April and June, down 7.7 percent from the same period last year, according to disclosures released by the federal government on Friday.